Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Stacy L. Moulder"'
Autor:
Lei Huo, Gaiane M. Rauch, Alyson Clayborn, Tanbin Rahman, Pamela McCarthy, David Ramirez, Elizabeth Ravenberg, Sadia Saleem, Stacy L. Moulder, Clinton Yam, W. Fraser Symmans, Jason B White, James Stec, Sausan Abouharb, Bora Lim, Jennifer K. Litton, Senthil Damodaran, Meghan Sri Karuturi, Ryan Sun
Publikováno v:
Investigational New Drugs. 39:509-515
Folate receptor alpha (FRα) has been reported to be expressed in up to 80% of triple-negative breast cancers (TNBC) with limited expression in normal tissues, making it a promising therapeutic target. Mirvetuximab soravtansine (mirvetuximab-s) is an
Autor:
Jessica W.T. Leung, Rosalind P. Candelaria, Jong Bum Son, Elsa Arribas, Peng Wei, Hagar S. Mahmoud, Jingfei Ma, Marion E. Scoggins, Kenneth R. Hess, Jennifer K. Litton, Abeer H Abdelhafez, Stacy L. Moulder, Vicente Valero, Elizabeth Ravenberg, Alastair M. Thompson, Gary J. Whitman, Huong T. Le-Petross, Beatriz E. Adrada, Tanya W. Moseley, Mark D. Pagel, Gaiane M. Rauch, Deanna L. Lane, Benjamin C. Musall, Ken Pin Hwang, Jason B White, Lumarie Santiago, Wei T. Yang
Publikováno v:
Breast Cancer Res Treat
PURPOSE: To determine if tumor necrosis by pretreatment breast MRI and its quantitative imaging characteristics are associated with response to NAST in TNBC. METHODS: This retrospective study included 85 TNBC patients (mean age 51.8 ± 13 years) with
Autor:
Helen Piwnica-Worms, Jennifer K. Litton, Banu Arun, Beatriz E. Adrada, Haven R. Garber, Gaiane M. Rauch, Debu Tripathy, Senthil Damodaran, Elizabeth A. Mittendorf, Vicente Valero, Rashmi Krishna Murthy, Fraser Symmans, Stacy L. Moulder, Lei Huo, Alastair M. Thompson, Naoto T. Ueno, Nuhad K. Ibrahim, Rosalind P. Candelaria, Bora Lim
Publikováno v:
Cancer Research. 80:P2-16
BACKGROUND: Current treatment for early stage triple negative breast cancer (TNBC) includes neoadjuvant systemic chemotherapy (NAST), which is used to assess disease biology and the need for adjuvant treatment in case of residual disease at the time
Autor:
Funda Meric-Bernstam, Rosalind P. Candelaria, Jennifer K. Litton, Gaiane M. Rauch, Beatriz E. Adrada, Colleen T. Eppig, Debu Tripathy, Kenneth R. Hess, Senthil Damodaran, Stacy L. Moulder, Bora Lim, Krzysztof J. Grzegorzewski, Ignacio I. Wistuba, Jason B White
Publikováno v:
Cancer Research. 80:OT2-06
Background:While TNBC patients with pathologic complete response (pCR) or residual cancer burden (RCB-I) have good survival rates, those with extensive residual disease (RCB-II or RCB-III) after neoadjuvant chemotherapy (NACT) have poor prognosis. Pa
Autor:
Abenaa M. Brewster, Rashmi Krishna Murthy, Alastair M. Thompson, Nuhad K. Ibrahim, Vicente Valero, Sarah M. DeSnyder, Senthil Damodaran, Helen Piwnica-Worms, Stacy L. Moulder, Gary J. Whitman, Thorunn Helgason, Jennifer K. Litton, Beatriz E. Adrada, Jill Schwartz-Gomez, Kenneth R. Hess, Carlos H. Barcenas, Banu Arun, Elizabeth A. Mittendorf, Marion E. Scoggins
Publikováno v:
J Clin Oncol
PURPOSE Talazoparib has demonstrated efficacy in patients with BRCA-positive metastatic breast cancer. This study evaluated the pathologic response of talazoparib alone for 6 months in patients with a known germline BRCA pathogenic variant (g BRCA-po
Autor:
Meghan Sri Karuturi, Tara Sanft, Denise A. Yardley, Angela DeMichele, Sibel Blau, Sara A. Hurvitz, Hope S. Rugo, Amy S. Clark, Amelia Zelnak, Aditya Bardia, Das Purkayastha, Cynthia X. Ma, Lowell L. Hart, Stacy L. Moulder
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 27, iss 15
Purpose: Standard-of-care treatment for metastatic hormone receptor–positive (HR+), HER2-negative (HER2−) breast cancer includes endocrine therapy (ET) combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i). Optimal treatment after progr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07d10c70a51cc377dfe2b31a20be89ec
https://escholarship.org/uc/item/0mj128b0
https://escholarship.org/uc/item/0mj128b0
Autor:
Francisco J. Esteva, Gabriel N. Hortobagyi, Sharon H. Giordano, Rashmi Krishna Murthy, Abenaa M. Brewster, Robert C. Bast, Stacy L. Moulder, Gaiane M. Rauch, Wei Yang, Ronald S. Walters, Daniel J. Booser, Vicente Valero, Clinton Yam, James L. Murray, Banu Arun
Publikováno v:
Investigational New Drugs. 36:1103-1109
Background Imatinib mesylate is a potent inhibitor of the Abl, KIT and platelet derived growth factor (PDGF) receptor tyrosine kinases. Preclinical data suggest that combining imatinib mesylate with anti-estrogen therapy may be synergistic in hormone
Autor:
Xiao Huang, Jun Zhao, Lei Huo, Yun Wu, Stacy L. Moulder, Dawen Sui, Wei Lien Wang, Hui Chen, Min Zhao, Yun Gong, Erika Resetkova, Jinxia Zhang, Hui Liu, Qingqing Ding, Hua Guo
Publikováno v:
Human pathology. 108
The Dako 28-8, Dako 22C3, and Ventana SP142 assays are among the approved programmed death ligand 1 (PD-L1) immunohistochemical companion/complementary diagnostics associated with cancer treatment. To address the concordance of these assays in triple
Autor:
Eleni Lagkadinou, Markus Joerger, Sara A. Hurvitz, Andrea Varga, Oliver Boix, Christine Rentzsch, Apostolia Maria Tsimberidou, Andreas Schneeweiss, Stacy L. Moulder, Matthias Ocker, Silke Thiele, Gary Wilkinson, Marion Rudolph, Dagmar Hess, Cynthia X. Ma
Publikováno v:
Cancers, vol 11, iss 12
Cancers
Volume 11
Issue 12
Cancers
Volume 11
Issue 12
This open-label, phase I first-in-human study (NCT01915576) of BAY 1125976, a highly specific and potent allosteric inhibitor of AKT1/2, aimed to evaluate the safety, pharmacokinetics, and maximum tolerated dose of BAY 1125976 in patients with advanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8e7672e0843827dd4b68b896f8dec21
https://escholarship.org/uc/item/3fn83958
https://escholarship.org/uc/item/3fn83958
Publikováno v:
American Society of Clinical Oncology Educational Book. :65-77
Metastatic breast cancer continues to be a life-threatening diagnosis that impacts hundreds of thousands of patients around the world. Targeted therapies are usually associated with less toxicity compared with cytotoxic chemotherapies and often induc